Our results reveal the role of oridonin as a small molecule proteostasis regulator that activates endogeneous HSF1 and support the potential clinical use of oridonin for BCR-ABL-expressing leukemia by inducing BCR-ABL degradation rather than inhibiting tyrosine kinase activity. Here, ABL1 is linked to leukemia.